Tables index

From

Computational Insights into the Drug Repurposing and Synergism of FDA-approved Influenza Drugs Binding with SARS-CoV-2 Protease against COVID-19

Shazia Parveen, Rua B. Alnoman, Abrar A. Bayazeed, Alaa M. Alqahtani

American Journal of Microbiological Research. 2020, 8(3), 93-102 doi:10.12691/ajmr-8-3-3
  • Table 1. Selected calculated physicochemical and pharmacokinetic properties of investigated FDA-approved influenza drugs
  • Table 2. Molecular docking analysis of investigated FDA-approved influenza drugs within the binding sites of SARS-CoV-2 (PDB ID: 6LU7) and SARS HCoV (PDB ID: 6NUR) and their binding energies in Kcal/mol
  • Table 3. Binding energies in Kcal/mol and amino acid residues involved in hydrogen bonding of investigated FDA-approved influenza drugs within the binding sites of SARS-CoV-2 and SARS HCoV
  • Table 4. The theoretical calculated conceptual DFT descriptors of investigated FDA-approved influenza drugs
  • Table 5. Thermal parameters (Hartree/Particle) (KJ/mol) and Dipole moment (Debye) of investigated FDA-approved influenza drugs